---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-050406"
form_type: "8-K"
ticker: "SNWV"
cik: "0001417663"
company_name: "SANUWAVE Health, Inc."
filed_at: "2025-11-07T23:59:59+00:00"
generated_at: "2026-05-16T23:01:14.735608+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sanuwave Q3 record revenue $11.5M (+22% YoY); guides Q4 $13-14M

## Summary
- Revenue of $11.5M, up 22% YoY and 13% sequentially; highest quarterly revenue in company history.
- GAAP operating income $1.5M vs $2.0M YoY, impacted by $1.4M stock-based compensation (none in Q3 2024).
- Net income $10.3M vs net loss of $20.7M YoY, driven by $6.1M non-cash derivative gain and $5.0M patent sale.
- Adjusted EBITDA grew to $3.5M from $2.1M YoY.
- Q4 2025 revenue guidance $13-14M; full-year FY2025 revenue guidance $44-45M (35-39% growth over FY2024).

## SEC filing metadata
- accession: 0001628280-25-050406
- form_type: 8-K
- ticker: SNWV
- cik: 0001417663
- company_name: SANUWAVE Health, Inc.
- filed_at: 2025-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1417663/000162828025050406/0001628280-25-050406-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1417663/000162828025050406/snwv-20251107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-050406
- JSON: https://secwatch.observer/filing/0001628280-25-050406.json
- Plain text: https://secwatch.observer/filing/0001628280-25-050406.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.